[1]
Kuwabara S, Misawa S. Chronic Inflammatory Demyelinating Polyneuropathy. Advances in experimental medicine and biology. 2019:1190():333-343. doi: 10.1007/978-981-32-9636-7_21. Epub
[PubMed PMID: 31760654]
Level 3 (low-level) evidence
[2]
Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry. 2019 Sep:90(9):981-987. doi: 10.1136/jnnp-2019-320314. Epub 2019 Apr 16
[PubMed PMID: 30992333]
[3]
Reynolds J, Sachs G, Stavros K. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. Rhode Island medical journal (2013). 2016 Dec 1:99(12):32-35
[PubMed PMID: 27902997]
[4]
Burns TM. Chronic inflammatory demyelinating polyradiculoneuropathy. Archives of neurology. 2004 Jun:61(6):973-5
[PubMed PMID: 15210544]
[5]
Hagen KM, Ousman SS. The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of neuroinflammation. 2021 Mar 22:18(1):78. doi: 10.1186/s12974-021-02113-2. Epub 2021 Mar 22
[PubMed PMID: 33752693]
[6]
Doneddu PE, Dentoni M, Nobile-Orazio E. Atypical chronic inflammatory demyelinating polyradiculoneuropathy: recent advances on classification, diagnosis, and pathogenesis. Current opinion in neurology. 2021 Oct 1:34(5):613-624. doi: 10.1097/WCO.0000000000000979. Epub
[PubMed PMID: 34267052]
Level 3 (low-level) evidence
[7]
Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nature reviews. Disease primers. 2018 Oct 11:4(1):31. doi: 10.1038/s41572-018-0027-2. Epub 2018 Oct 11
[PubMed PMID: 30310069]
[8]
Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, Kuwahara M, Suzuki H, Kusunoki S, Fujimoto Y, Ikezoe K, Kishida H, Tanaka F, Matsushita T, Murai H, Kira J. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Annals of clinical and translational neurology. 2015 Oct:2(10):960-71. doi: 10.1002/acn3.248. Epub 2015 Sep 11
[PubMed PMID: 26478896]
[9]
Mathey EK, Garg N, Park SB, Nguyen T, Baker S, Yuki N, Yiannikas C, Lin CS, Spies JM, Ghaoui R, Barnett MH, Vucic S, Pollard JD, Kiernan MC. Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. Journal of neuroimmunology. 2017 Aug 15:309():41-46. doi: 10.1016/j.jneuroim.2017.05.002. Epub 2017 May 13
[PubMed PMID: 28601286]
[10]
Doppler K, Appeltshauser L, Wilhelmi K, Villmann C, Dib-Hajj SD, Waxman SG, Mäurer M, Weishaupt A, Sommer C. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. Journal of neurology, neurosurgery, and psychiatry. 2015 Jul:86(7):720-8. doi: 10.1136/jnnp-2014-309916. Epub 2015 Feb 18
[PubMed PMID: 25694474]
[11]
Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. The Lancet. Neurology. 2010 Apr:9(4):402-12. doi: 10.1016/S1474-4422(10)70041-7. Epub
[PubMed PMID: 20298964]
[12]
Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME, Anaya JM. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. Journal of autoimmunity. 2019 Aug:102():8-37. doi: 10.1016/j.jaut.2019.04.021. Epub 2019 May 6
[PubMed PMID: 31072742]
[13]
Kiefer R, Kieseier BC, Stoll G, Hartung HP. The role of macrophages in immune-mediated damage to the peripheral nervous system. Progress in neurobiology. 2001 Jun:64(2):109-27
[PubMed PMID: 11240209]
[14]
Dimachkie MM, Barohn RJ. Chronic inflammatory demyelinating polyneuropathy. Current treatment options in neurology. 2013 Jun:15(3):350-66. doi: 10.1007/s11940-013-0229-6. Epub
[PubMed PMID: 23564314]
[15]
Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nature reviews. Neurology. 2014 Aug:10(8):435-46. doi: 10.1038/nrneurol.2014.117. Epub 2014 Jul 1
[PubMed PMID: 24980070]
[16]
McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain : a journal of neurology. 1987 Dec:110 ( Pt 6)():1617-30
[PubMed PMID: 3427403]
Level 3 (low-level) evidence
[17]
Jha S, Ansari M, Sonkar K, Paliwal V. Unusual features in chronic inflammatory demyelinating polyneuropathy: Good outcome after prolonged ventilatory support. Journal of neurosciences in rural practice. 2011 Jul:2(2):171-3. doi: 10.4103/0976-3147.83586. Epub
[PubMed PMID: 21897683]
[18]
Kuwabara S, Misawa S, Mori M. Atypical chronic inflammatory demyelinating polyneuropathies. Journal of neurology, neurosurgery, and psychiatry. 2019 Feb:90(2):121. doi: 10.1136/jnnp-2018-319411. Epub 2018 Oct 8
[PubMed PMID: 30297522]
[19]
Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015 Aug 11:85(6):498-504. doi: 10.1212/WNL.0000000000001833. Epub 2015 Jul 15
[PubMed PMID: 26180143]
[20]
Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. Journal of the peripheral nervous system : JPNS. 2021 Sep:26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30
[PubMed PMID: 34085743]
[21]
Goedee HS, van der Pol WL, van Asseldonk JH, Franssen H, Notermans NC, Vrancken AJ, van Es MA, Nikolakopoulos S, Visser LH, van den Berg LH. Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies. Neurology. 2017 Jan 10:88(2):143-151. doi: 10.1212/WNL.0000000000003483. Epub 2016 Dec 7
[PubMed PMID: 27927940]
[22]
Di Pasquale A, Morino S, Loreti S, Bucci E, Vanacore N, Antonini G. Peripheral nerve ultrasound changes in CIDP and correlations with nerve conduction velocity. Neurology. 2015 Feb 24:84(8):803-9. doi: 10.1212/WNL.0000000000001291. Epub 2015 Jan 28
[PubMed PMID: 25632087]
[23]
Katzberg HD, Latov N, Walker FO. Measuring disease activity and clinical response during maintenance therapy in CIDP: from ICE trial outcome measures to future clinical biomarkers. Neurodegenerative disease management. 2017 Apr:7(2):147-156. doi: 10.2217/nmt-2016-0058. Epub 2017 Jan 23
[PubMed PMID: 28112008]
[24]
Hiwatashi A, Togao O, Yamashita K, Kikuchi K, Momosaka D, Nakatake H, Yamasaki R, Ogata H, Yoneyama M, Kira JI, Honda H. Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. Magnetic resonance imaging. 2019 Jan:55():112-117. doi: 10.1016/j.mri.2018.09.025. Epub 2018 Sep 25
[PubMed PMID: 30266626]
[25]
Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000 Feb 8:54(3):615-20
[PubMed PMID: 10680792]
[26]
Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle & nerve. 2009 Feb:39(2):206-20. doi: 10.1002/mus.21199. Epub
[PubMed PMID: 19145651]
[27]
Kimura A, Sakurai T, Koumura A, Yamada M, Hayashi Y, Tanaka Y, Hozumi I, Yoshino H, Yuasa T, Inuzuka T. Motor-dominant chronic inflammatory demyelinating polyneuropathy. Journal of neurology. 2010 Apr:257(4):621-9. doi: 10.1007/s00415-009-5386-x. Epub 2009 Nov 22
[PubMed PMID: 20361294]
[28]
Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. Journal of clinical neuromuscular disease. 2012 Mar:13(3):149-52. doi: 10.1097/CND.0b013e31822484fb. Epub
[PubMed PMID: 22538310]
[29]
Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. Journal of neurology, neurosurgery, and psychiatry. 1992 Aug:55(8):677-80
[PubMed PMID: 1326601]
[30]
Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of neurology. 1994 Dec:36(6):838-45
[PubMed PMID: 7998769]
[31]
Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. The Cochrane database of systematic reviews. 2017 Jan 13:1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2. Epub 2017 Jan 13
[PubMed PMID: 28084646]
Level 3 (low-level) evidence
[32]
van Lieverloo GGA, Peric S, Doneddu PE, Gallia F, Nikolic A, Wieske L, Verhamme C, van Schaik IN, Nobile-Orazio E, Basta I, Eftimov F. Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. Journal of neurology. 2018 Sep:265(9):2052-2059. doi: 10.1007/s00415-018-8948-y. Epub 2018 Jul 2
[PubMed PMID: 29968199]
Level 2 (mid-level) evidence
[34]
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. The Lancet. Neurology. 2008 Feb:7(2):136-44. doi: 10.1016/S1474-4422(07)70329-0. Epub
[PubMed PMID: 18178525]
Level 1 (high-level) evidence
[35]
Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology. 2012 Apr 3:78(14):1079-84. doi: 10.1212/WNL.0b013e31824e8f84. Epub 2012 Mar 21
[PubMed PMID: 22442436]
[36]
Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MM. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. Journal of the peripheral nervous system : JPNS. 2016 Mar:21(1):33-7. doi: 10.1111/jns.12158. Epub
[PubMed PMID: 26757367]
[37]
Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. Journal of neuroimmunology. 2011 Feb:231(1-2):61-9. doi: 10.1016/j.jneuroim.2010.09.015. Epub 2010 Nov 5
[PubMed PMID: 21056913]
[38]
Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. Journal of the neurological sciences. 2017 Jul 15:378():19-25. doi: 10.1016/j.jns.2017.04.039. Epub 2017 Apr 24
[PubMed PMID: 28566163]
[39]
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, PATH study group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology. 2018 Jan:17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6
[PubMed PMID: 29122523]
Level 1 (high-level) evidence
[40]
Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Frontiers in immunology. 2018:9():1299. doi: 10.3389/fimmu.2018.01299. Epub 2018 Jun 8
[PubMed PMID: 29951056]
[41]
Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. The Cochrane database of systematic reviews. 2015 Aug 25:2015(8):CD003906. doi: 10.1002/14651858.CD003906.pub4. Epub 2015 Aug 25
[PubMed PMID: 26305459]
Level 1 (high-level) evidence
[42]
Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. The Cochrane database of systematic reviews. 2012 Sep 12:(9):CD003906. doi: 10.1002/14651858.CD003906.pub3. Epub 2012 Sep 12
[PubMed PMID: 22972066]
[43]
RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. The Lancet. Neurology. 2009 Feb:8(2):158-64. doi: 10.1016/S1474-4422(08)70299-0. Epub 2009 Jan 10
[PubMed PMID: 19136303]
Level 3 (low-level) evidence
[44]
Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999 Jul 13:53(1):57-61
[PubMed PMID: 10408537]
Level 1 (high-level) evidence
[45]
Kuntzer T, Radziwill AJ, Lettry-Trouillat R, Naegeli C, Ochsner F, Erne B, Steck AJ, Bogousslavsky J. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology. 1999 Oct 12:53(6):1364-5
[PubMed PMID: 10522905]
[46]
Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Therapeutic advances in neurological disorders. 2012 Nov:5(6):359-73. doi: 10.1177/1756285612457215. Epub
[PubMed PMID: 23139706]
Level 3 (low-level) evidence
[47]
Mauermann ML, Sorenson EJ, Dispenzieri A, Mandrekar J, Suarez GA, Dyck PJ, Dyck PJ. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. Journal of neurology, neurosurgery, and psychiatry. 2012 May:83(5):480-6. doi: 10.1136/jnnp-2011-301472. Epub 2012 Mar 6
[PubMed PMID: 22396441]
[48]
Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Théaudin M, Adam C, Arnulf B, Adams D. Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology. 2018 Jul 10:91(2):e143-e152. doi: 10.1212/WNL.0000000000005777. Epub 2018 Jun 15
[PubMed PMID: 29907605]
[50]
Mygland A, Monstad P, Vedeler C. Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle & nerve. 2005 May:31(5):589-93
[PubMed PMID: 15742374]
[51]
Dyck PJB, Tracy JA. History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clinic proceedings. 2018 Jun:93(6):777-793. doi: 10.1016/j.mayocp.2018.03.026. Epub
[PubMed PMID: 29866282]
[52]
Dyck PJ, Taylor BV, Davies JL, Mauermann ML, Litchy WJ, Klein CJ, Dyck PJ. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Muscle & nerve. 2015 Oct:52(4):488-97. doi: 10.1002/mus.24707. Epub 2015 Aug 13
[PubMed PMID: 25976871]
[53]
Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy. 1991:11(5):119S-125S
[PubMed PMID: 1745617]